000310362 001__ 310362
000310362 005__ 20260311121051.0
000310362 0247_ $$2doi$$a10.1016/j.jhep.2026.02.027
000310362 0247_ $$2pmid$$apmid:41794137
000310362 0247_ $$2ISSN$$a0168-8278
000310362 0247_ $$2ISSN$$a1600-0641
000310362 037__ $$aDKFZ-2026-00558
000310362 041__ $$aEnglish
000310362 082__ $$a610
000310362 1001_ $$aMüller, Lukas$$b0
000310362 245__ $$aBCLC classification and AI-based image quantification: What is meant to be will come together - but how and when?: BCLC and AI-based image quantification.
000310362 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2026
000310362 3367_ $$2DRIVER$$aarticle
000310362 3367_ $$2DataCite$$aOutput Types/Journal article
000310362 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1773225446_3298573
000310362 3367_ $$2BibTeX$$aARTICLE
000310362 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000310362 3367_ $$00$$2EndNote$$aJournal Article
000310362 500__ $$a#NCTZFB9# / epub
000310362 520__ $$aThe Barcelona Clinic Liver Cancer (BCLC) classification has been the mainstay for prognostic assessment and initial treatment selection in hepatocellular carcinoma (HCC) for more than two decades. It is widely clinically accepted and has been reaffirmed in the recently renewed European Association for the Study of the Liver (EASL) Clinical Practice Guidelines on the management of HCC. Its design is based on simple clinical and imaging parameters, which makes it highly applicable in clinical routine. However, it does not fully utilize all information, which is potentially encoded in routine radiology imaging. With artificial intelligence (AI) methods now maturing, we have a robust way to extract and quantify digital imaging features fully automatically without much user input and with high precision. Therefore, AI could bridge quantitative imaging into clinical decision-making, together with the existing BCLC classification. However, despite substantial AI advancements in many fields such as automated tumor volumetry, radiomics, detection of metastatic lesions, and even capturing opportunistic imaging biomarkers, a translational gap persists. While challenges related to technical, administrative, and cost-related, but also training-related factors have to be taken into account, a certain aversion to change, as well as absence of standardized AI validation and missing workflow integration hamper the clinical implementation in routine care. This article aims to evaluate current AI-quantified imaging parameters and their potential for synergy with the established BCLC classification.
000310362 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000310362 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000310362 650_7 $$2Other$$aArtificial intelligence
000310362 650_7 $$2Other$$aClassification
000310362 650_7 $$2Other$$aHepatocellular Carcinoma
000310362 650_7 $$2Other$$aPrognosis
000310362 650_7 $$2Other$$aQuantification
000310362 7001_ $$0P:(DE-He78)761f5d0f73e0d8f170394b29448a9e8d$$aKather, Jakob Nikolas$$b1$$udkfz
000310362 7001_ $$aMarquardt, Jens U$$b2
000310362 7001_ $$aReig, Maria$$b3
000310362 7001_ $$aWang, Qiang$$b4
000310362 7001_ $$aPinto Dos Santos, Daniel$$b5
000310362 7001_ $$aKloeckner, Roman$$b6
000310362 773__ $$0PERI:(DE-600)2027112-8$$a10.1016/j.jhep.2026.02.027$$gp. S0168827826001212$$pnn$$tJournal of hepatology$$vnn$$x0168-8278$$y2026
000310362 909CO $$ooai:inrepo02.dkfz.de:310362$$pVDB
000310362 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)761f5d0f73e0d8f170394b29448a9e8d$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000310362 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000310362 9141_ $$y2026
000310362 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2025-11-06$$wger
000310362 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ HEPATOL : 2022$$d2025-11-06
000310362 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-11-06
000310362 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-11-06
000310362 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-11-06
000310362 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-11-06
000310362 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-11-06
000310362 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-11-06
000310362 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-11-06
000310362 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-11-06
000310362 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-11-06
000310362 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-11-06
000310362 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-11-06
000310362 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-11-06
000310362 915__ $$0StatID:(DE-HGF)9925$$2StatID$$aIF >= 25$$bJ HEPATOL : 2022$$d2025-11-06
000310362 9201_ $$0I:(DE-He78)HD02-20160331$$kHD02$$lKoordinierungsstelle NCT Heidelberg$$x0
000310362 980__ $$ajournal
000310362 980__ $$aVDB
000310362 980__ $$aI:(DE-He78)HD02-20160331
000310362 980__ $$aUNRESTRICTED